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Spontaneous and “event-related” motor cortex oscillations in the beta (15–30Hz)
frequency range are well-established phenomena. However, the precise functional
significance of these features is uncertain. An understanding of the specific function
is of importance for the treatment of Parkinson’s disease (PD), where attenuation of
augmented beta throughout the motor network coincides with functional improvement.
Previous research using a discrete movement task identified normalization of elevated
spontaneous beta and postmovement beta rebound following GABAergic modulation.
Here, we explore the effects of the gamma-aminobutyric acid type A modulator,
zolpidem, on beta power during the performance of serial movement in 17
(15M, 2F; mean age, 66 ± 6.3 years) PD patients, using a repeated-measures,
double-blinded, randomized, placebo-control design. Motor symptoms were monitored
before and after treatment, using time-based Unified Parkinson’s Disease Rating Scale
measurements and beta oscillations in primary motor cortex (M1) were measured
during a serial-movement task, using magnetoencephalography. We demonstrate that a
cumulative increase in M1 beta power during a 10-s tapping trial is reduced following
zolpidem, but not placebo, which is accompanied by an improvement in movement
speed and efficacy. This work provides a clear mechanism for the generation of
abnormally elevated beta power in PD and demonstrates that perimovement beta
accumulation drives the slowing, and impaired initiation, of movement. These findings
further indicate a role for GABAergic modulation in bradykinesia in PD, which merits
further exploration as a therapeutic target.
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INTRODUCTION
Spontaneous beta frequency (15–30Hz) oscillations are a
prominent electrophysiological signature of the primary motor
cortex (M1) in humans (1, 2) and animal models (3). Beta
oscillations have been posited as an “idling” rhythm of the motor
system (4), in line with the conceptual need for a carrier signal
to facilitate temporal binding of functional performance (5).
From a functional perspective, beta power in M1 modulates
in a task-dependent manner in relation to various phases of
movement. Specifically, a bilateral reduction in beta is observed
during movement preparation (6), with a further reduction in
power at the onset of movement, referred to asmovement-related
beta desynchronization (MRBD) (7, 8). Beta power appears to
be minimized during dynamic movement periods (9–11), where
a reduction in beta power lasts as long as the total movement
(4). Conversely, there appears to be an increase in beta power
associated with static postural maintenance (12–14).
Following the completion or termination of movement, there
is a transient increase in beta oscillatory power, which is elevated
above the premovement baseline (1, 4, 8, 15), a phenomenon
referred to as postmovement beta rebound (PMBR). With
regard to functional significance, MRBD is a prerequisite for
recruitment of functional assemblies ahead of movement (16),
but is not dependent upon force, speed, direction (17), or
movement time (18). The functional significance of PMBR is
unclear, although it has been postulated as a marker of sensory
reafference following movement (19) and appears to serve an
inhibitory function (20). The interaction between MRBD and
PMBR during the performance of serial movements is uncertain.
However, it has been shown that beta activity is suppressed
according to the likelihood of new motor processing, such
that phasic suppression of beta activity before movement is
replaced by a persistent suppression during a sequence of related
movements, such as in finger tapping (FT) (21). In healthy
humans, ability to effectively initiate movement is dependent
upon an ability to achieve an absolute level of premovement
desynchronization (22), and fast FT produces a persistent state
of cortical beta desynchronization during movement (23).
In Parkinson’s disease (PD), exaggerated beta oscillations
are observed in recordings from subcortical structures, such
as the subthalamic nucleus (STN) and cortex of both animal
models (24–26) and PD patients (27, 28). There is some
uncertainty regarding the importance of spontaneous cortical
beta power in PD, as observations are typically in early-stage
PD and show variation between participants (29), but an
association between abnormal premovement desynchronization
and deficits in movement initiation supports a role in akinetic
symptoms in PD (30). Similarly, several studies report that
this exaggerated beta power is attenuated following treatment
with either levodopa (31, 32) or deep brain stimulation (33,
34), both of which are associated with relief of PD symptoms.
We have previously reported that subsedative doses (2–5mg)
of the gamma-aminobutyric acid type A (GABAA) alpha-1
receptor modulator zolpidem improves cognitive and motor
abilities of patients after stroke (35) and idiopathic PD (29),
coincident with a reduction in beta power. This is consistent
with previously observed GABA-mediated improvements in
PD (36). In healthy controls, elevation of endogenous GABA
levels is known to increase baseline beta power (37), as seen
following administration of benzodiazepines (1, 2). From a
functional perspective, the benzodiazepine Bromazepam, which
has high alpha-2 and low alpha-1 subunit affinity for the
GABAA receptor, has been shown to have positive effects
on motor learning involving focused attention in healthy
participants (38).
Our previous research using magnetoencephalography
(MEG) in PD, used the sedative hypnotic zolpidem to modulate
activity at the gamma-aminobutyric acid type A (GABA-A)
alpha-1 subunit. This demonstrated that PD patients exhibit
impaired desynchronization in the movement preparation phase
and increased amplitude and latency of the PMBR phase (29).
These differences were reduced following administration of
zolpidem and accompanied by improvement in symptomatic
severity, measured bymotor examination (Part III) of the Unified
Parkinson’s Disease Rating Scale (UPDRS). Given the evidence
surrounding the potential for exaggerated beta in the motor
system to impair effective movement in PD, via impediment of
desynchronization, it is important to understand the potential
role of perimovement beta power in this process. Here, we
address this question through the investigation of oscillatory
power, using MEG, in a serial movement task, using a simple FT
paradigm. Following our previous study (29), we further explore
the mechanisms of GABA-mediated functional improvements
with low-dose zolpidem, in a cohort of PD patients presenting
with unilateral symptoms.
We hypothesize that increased PMBR amplitude and latency
in PD will produce a progressive accumulation of beta power
over time, resulting in higher perimovement beta amplitude
that impairs the ability to initiate subsequent movements.
Furthermore, we postulate that greater perimovement beta power
will coincide with an increased intertap interval (ITI). We predict
that zolpidem will reduce perimovement beta power, affording
an improvement in the performance of the finger-tapping speed
and stability.
METHODS
Participant Training and Assessment
We recruited 17 participants (15M, 2F), mean age of 66 ±
6.3 years, with a history of unilateral PD symptoms, following
previous research (29). Consistent with ethical approval,
patients continued with their prescribed medication during their
participation in the experiment. Details of medication and other
particulars were recorded for each participant (see Table 1 for
details), although individual medication doses were not recorded.
Drug and control experiments were conducted at the same
time interval following medication to control for effects of
other drugs. Five participants were eventually excluded from
the analysis as bilateral impairments were observed at baseline.
Participants attended the laboratory over 2 days, on which
identical experimental protocols were used, with the exception of
drug condition. A double-blinded and randomized approach was
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TABLE 1 | Participant information summary.
Patient
ID
Gender Dominant
hand
Age
(years)
Medication Time since
diagnosis (years)
Impaired
side (L/R)
1 UPDRS
zolpidem#
1 UPDRS
Placebo#
1 M R 60 Ropinirole,
Sinemeta
5 L −12.80 2.07
2 F R 67 Sinemet plus 1 L −1.41 −4.54
3 M R 67 Madoparb,
Pramiprexole,
Rasagline,
Sinemeta
* R −12.79 3.03
4 M R 72 Amantadine,
Ropinorole CR,
Sinemet CRa,
Stalevoc
* L −12.05 −3.39
5 F R 60 Co-careldopad,
Rasagiline
12 L −1.17 9.62
6 M R 67 Madoparb,
Ropinirole,
Selegeline
6 R −7.44 4.06
7 M R 82 Sinemet Plusa,
Selegeline
5 R −5.54 11.18
8 M R 50 Ropinirole MR * L −13.45 −5.25
9 M R 72 Pramiprexole
CR
3 R −10.96 −12.54
10 M R 69 Requip XLe,
Stalevoc
6 R −14.06 −12.63
11 M R 57 Pramiprexole,
Selegeline
* R −2.37 −8.48
12 M R 67 Rasagiline,
Sinemeta
4 L −5.75 2.23
aCarbidopa/L-dopa, bbenserazide/L-dopa, cL- dopa/carbidopa/entacapone, dcarbidopa/L-dopa, eropinerole. MR, modified release; CR, controlled release. #Mean change in time
taken to complete each motor performance measurements. *Time since diagnosis longer than 5-years, exact duration data were not available.
used to assign the order for each participant to either the drug-
active (zolpidem) or placebo session. Before each neuroimaging
experiment, each participant was trained in the motor task.
Specifically, participants placed their hands on a magnetically
silent acrylic plate, with the position of a flexible paddle beneath
the index finger monitored using infrared light.
Motor Task and Symptom Assessment
As part of a functional task to localize M1, based upon PMBR
(8, 15, 39), participants performed a visual reaction time task,
in which they responded as quickly as possible to a change in
visual cue with abduction of either the left or right index finger
[e.g., (39)].
The serial motor finger-tapping task consisted of six 10-
s tapping trials, interleaved by 15-s periods of inactive rest.
Participants were instructed to tap as quickly as possible
following the onset of a “Start” cue, until the presentation of
a “Stop” cue. Stimuli were presented on a projector screen,
1m in front of the participant. Finger taps were recorded and
analyzed, based upon triggers digitized from the infrared signals.
The participant was instructed to relax their hand when the
cue disappeared. Cue onset was jittered to minimize prediction
effects. Participants rested their arm in a comfortable position,
with the elbow and the lower arm resting on a flat surface.
Before each MEG session, participants completed a series of
tasks included in the UPDRS motor examination (Part III). This
included FT, hand movement, rapid alternating movement, leg
agility (LA), time to stand, and time to walk. Performance was
quantified based upon the time taken to complete each task,
rather than the typical 5-point scale, to increase sensitivity and
reduce the variance of intrarater assessment (see Figure 1 for
details). For each task, the rater used a stopwatch to record the
time taken to complete a predetermined number of repetitions
or distance.
MEG and EMG Recordings
In each experiment, participants with normal or corrected to
normal vision were seated in a 306-channel MEG system (Elekta,
Finland). MEG data were acquired at a sampling rate of 1,000Hz
with a 50-Hz notch filter and 0.1–300Hz bandpass filters.
MEG data were coregistered with each participant’s anatomical
MRI, obtained using a 3-T MRI system (Siemens Magnetom
Trio). This was achieved through surface matching of the
MRI with a three-dimensional digitization of the participant’s
scalp (Fastrak, Polhemus, USA). Head position was monitored
throughout, based upon the digitized position of five surface-
mounted electromagnetic coils, positioned around the head.
Electromyography (EMG), native to the MEG system, was used
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FIGURE 1 | Motor performance measurements following placebo and zolpidem. (A) Total change (%) in motor performance score following placebo (black) and
zolpidem (red). # INDICATES significant difference (p = 0.003) between conditions. (B) Motor performance, based upon Unified Parkinson’s Disease Rating Scale
(UPDRS) part III, was quantified (time to complete) and improvement between BL and drug condition calculated. Change (%) in scores are shown for placebo (black)
and zolpidem (red) with significant change (*p < 0.05) indicated for finger tapping and leg agility (FT, finger tapping; HM, hand movement; RAM, rapid alternating
movement; LA, leg agility; TS, time to stand; TW, time to walk).
to record muscle activity from two disk electrodes placed upon
the first dorsal interosseous muscle, simultaneously measured
with the MEG acquisition.
At the end of the baseline (BL) recording session, participants
were administered either oral zolpidem (0.05 mg/kg) or placebo,
consistent with previously reported effective subsedative doses
(35). An identical second MEG recording session was initiated
50min after the zolpidem administration, with participants
required to repeat the same rest and movement periods.
Participants therefore completed a total of four MEG sessions
(BL, zolpidem and BL, placebo).
Data Analysis
Left and right M1 was localized using the synthetic aperture
magnetometry beamforming method (40). Specifically, following
finger movement, we identified the location of maximal
contralateral beta power (15–30Hz) increase in the PMBR
period (500–1,000ms postmovement termination) compared
to rest (−2,000 to −1,500ms premovement onset), following
previous studies (8). Regions of interest identified from the
beamforming analysis were used to determine the placement
of virtual electrodes (40, 41), which were used to reconstruct
neuronal network activity, specific to M1, over the envelope of
the entire experiment. The power profile of the oscillatory activity
was determined using Morlet wavelet time–frequency analysis of
the virtual electrode output over the 1–100Hz range in frequency
bins of 0.5Hz. For each participant, the individual beta peak was
determined as the maximal peak of power spectral density in the
15–35Hz range. This peak was then used to compute beta power
changes in all subsequent analyses. Data from M1, contralateral
to the affected hand, were grouped for further analysis and
comparisons made between the baseline and drug (zolpidem)
and control (placebo) conditions.
To determine the extent to which beta power increases
during serial movement tasks (perimovement period), we used
a cumulative summation (cusum) computation (Matlab R2019,
Mathworks USA) to identify the progressive accumulation of
power in the beta frequency range during the FT exercise.
Specifically, the envelope of peak beta power during FT was
reconstructed for each participant, in each condition. Data were
converted to a zero-mean distribution, followed by sequential
computation of the summed value of each sample over a 10-s
period. We further explored whether a causal relationship exists
between augmented beta and impaired sequential movement in
PD. Peak beta power in the virtual electrode plots were used to
reconstruct the profile of beta fluctuation associated with each tap
during FT. The ITI and intertap variance (ITV) were computed
as the mean and range, respectively, of the time between taps
during the tapping task. Beta power was computed following
each finger tap for each individual, for each condition. This
was based upon the maximal beta amplitude in the interval
between completion and initiation of movements, derived from
the rectified EMG. Subsequently, we computed the number of
taps in the average ITI following each beta peak to determine
the relationship between beta amplitude and movement ability.
All data are graphically represented as mean normalized change
(%) ± SD. Groups were analyzed using two-way repeated
measures ANOVA, with within-subject factors of “condition”
(pre-/postdrug treatment) and “drug” (placebo/zolpidem). Post-
hoc t-test comparisons are reported with Sidak’s correction for
comparisons. When only two groups were compared, a two-
tailed paired t-test was used. No significant interactions were
observed unless otherwise stated in the text.
RESULTS
UPDRS Measures
The time-based UPDRS approach demonstrated a significant
effect of time on the improvement in the symptomatic severity
of participants [F1,11 = 12.00, p = 0.003]. Post-hoc analysis
confirmed a significant improvement following administration
of zolpidem [t11 = 3.34, p = 0.007] that was not seen following
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placebo [t11 = 1.557, p = 0.25] (Figure 1A). Further analysis
of individual symptoms, using Sidak’s multiple comparison test,
confirmed a significant reduction [t11 = 2.36, p = 0.04; −1.59
± 0.62 s] in the time taken to complete the FT task (20
taps) following zolpidem, which was not seen in the placebo
condition [t11 = 0.19, p = 0.85; 0.28 ± 1.2 s] (Figure 1B, FT).
Further analysis, using one-way repeated measures ANOVA,
confirmed that there were no significant differences in tapping
performance between the six tapping trials [F(5,66) = 1.97, p =
0.12]; confirming that fatigue was not a driver of the observed
changes. In addition, a similar improvement was observed in
the LA task, where significant reduction in the time taken to
complete 20 leg lifts following zolpidem [t11 = 2.39, p = 0.04;
−0.72 ± 0.91 s] was not observed following placebo [t11 = 1.56,
p= 0.24;−0.42± 0.80 s) (Figure 1B, LA).
Reaction Time and Tapping Speed
Measurement of choice reaction time, using randomized left and
right index finger movement cues, demonstrated no significant
main effect of condition [F1,11 = 0.0003, p = 0.98] or drug
[F1,1 = 0.09, p = 0.78] on the reaction time speed (placebo
= 29.8 ± 31.8ms; zolpidem = −28.5 ± 35.6ms) (Figure 2A).
Analysis of the FT task, completed in the MEG, was consistent
with UPDRS findings (Figure 1B). A significant increase was
observed in the number of taps completed following zolpidem
[t11 = 2.61, p = 0.03; 1.21 ± 0.56 taps], which was not observed
following placebo [t11 = 2.08, p = 0.11; 2.17 ± 1.34 taps)
(Figure 2B). Consistent with an increase in tapping speed, a
significant reduction in the ITI was observed following zolpidem
[t11 = 2.85, p = 0.02; −26.68 ± 10.49ms] but not placebo [t11
= 0.25, p = 0.96; 2.46 ± 5.10ms) (Figure 2C). Furthermore,
analysis of the ITV, which reflects the number of hastening and
faltering events during the tapping task, revealed a significant
reduction of ITV following zolpidem [t11 = 2.55, p = 0.05;
−35.58 ± 17.38ms] but not placebo [t11 = 0.29, p = 0.95;
15.08 ± 17.86ms) (Figure 2D). Analysis of tremor amplitude, as
measured by the 3–7Hz frequency range power in the rectified
EMG, revealed a significant main effect of drug [F1,11 = 9.49, p=
0.03], confirmed by post-hoc analysis as an amplitude reduction
following zolpidem [t11= 2.80, p= 0.04;−12.58± 16.04µV/Hz]
but not placebo [t11 = 0.05, p = 0.99; 1.52 ± 2.50 µV/Hz]
(Figure 2Ei). This reduction is evident in the mean EMG power
spectral density measures for each condition (Figure 2Eii).
Beta Power and Movement Ability
Time–frequency analysis revealed an increase in beta power
in the 10-s tapping period compared to the 2-s premovement
baseline, which was more pronounced in the placebo than
the zolpidem condition (Figures 3A,B). The accumulation of
beta power over the 10-s period of FT, in each condition, was
computed using the cumulative summation (cumsum) method
(Matlab R2019, Mathworks USA). This revealed a significant
main effect of drug [F1,11 = 3.96, p = 0.05), characterized
by substantial accumulation of beta power in the baseline
and placebo conditions but not in the zolpidem condition,
where beta was suppressed below the premovement baseline
(Figure 3C). Post-hoc analysis confirmed a significant reduction
in the accumulation of beta power following zolpidem [−740
± 548 nAm2/Hz; t11 = 2.39, p = 0.03] that was not observed
following placebo [1,763± 1,389 nAm2/Hz; t11 = 0.66, p= 0.52)
(Figure 3D). Frequency analysis, visualized as power spectral
density estimation (Figure 3E) demonstrates that the reduction
in cumulative beta power occurs with a peak at ∼25Hz, when
compared to placebo. Further analysis of peak intertap beta,
derived from the maximal beta amplitude in the interval between
finger taps, revealed a significant main effect of drug [F1,11 =
7.28, p = 0.012] on intertap beta amplitude following zolpidem
(−258.6 ± 123.5 nA/Hz: t11 = 3.91, p = 0.026] but not placebo
[−0.85± 2.70%: t11 = 0.84, p= 0.11; 42.3± 126.8 nA/Hz].
Subsequent analysis of the causal relationship between
perimovement beta power and movement ability was performed
by computing the number of finger taps, derived from the
rectified EMG, occurring within each participant’s mean ITI
following each intertap beta peak (Figure 4A). In the baseline
and placebo conditions, an inverse correlation was observed
between the number of taps performed and beta amplitude
(R2 = 0.96, p = 0.003). Following administration of zolpidem, a
substantial reduction in beta power was observed, with greatest
reduction associated with the absence of taps (R2 = 0.58, p =
0.14, Figure 4B).
Power-independent analysis of the number of taps/peak-beta
event revealed no significant change [t11 = 1.21, p = 0.28] in
the mean number of taps following each peak between placebo
(1.48 ± 0.95) and zolpidem (1.36 ± 0.31) conditions. However,
a substantial change in the variance was observed, indicating a
reduction in the number of zero and multiple taps (Figure 4C).
Analysis of the individual beta peak events revealed a significant
main effect of drug on the number of single taps [F1,11 =
6.02, p = 0.03]. Sidak corrected post-hoc comparison confirmed
a significant increase in the number of single taps following
zolpidem [20.04 ± 1.52%; t11 = 3.36, p = 0.0079], but not
following placebo [6.78 ± 9.83%: t11 = 0.6, p = 0.62]. This is
likely to be accounted for by modest and non-significant changes
to the number of missed and multiple taps (Figure 4D).
DISCUSSION
This study expands upon previous observations that PMBR
is elevated in PD patients to demonstrate a progressive
accumulation of beta power during the course of a serial
tapping task. Further analysis shows that the ability to generate
individual taps is directly associated with beta power in
the preceding interval. Improvement in motor performance,
observed following administration of zolpidem, is associated with
a reduction in the accumulation of perimovement beta power.
Perimovement Beta as an Inhibitory Signal
in PD
These experiments demonstrate an important mechanism by
which abnormally elevated beta power following movement
may impair the ability of patients to perform subsequent and
therefore serial movements in PD. As demonstrated in previous
experiments, there appears to be an augmentation of beta
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FIGURE 2 | Functional measurements before and after placebo and zolpidem during magnetoencephalography (MEG) scanning. (A) Change (%) in latency of reaction
time (RT) measured during the cued index-finger response task before and after placebo (black) and zolpidem (red). No significant effect of drug was observed (p =
0.78). (B) Mean change (%) in the number of taps completed in 10 s following placebo (black) and zolpidem (red) shows a significant difference (#) between
conditions, as a result of an increase in the zolpidem condition (*p = 0.03). (C) Change (%) in the mean ITI during the completion of the 10-s tapping task following
placebo (black) and zolpidem (red). Shows a significant difference (#) between conditions (p = 0.02). (D) Change (%) in the intertap variance (SD) following placebo
(black) and zolpidem (red). Shows a significant difference (#) between conditions (p = 0.05). (Ei) Change (%) in EMG power in the 3–7Hz frequency range following
placebo (black) and zolpidem (red), which reveals a significant difference (#) following zolpidem (p = 0.04). (Eii) Shows the complete power spectral density profile of
the EMG during baseline and after placebo and zolpidem. Gray box shows 3–7Hz range.
oscillatory power throughout the motor network of PD patients
(27, 28, 42), which appears to be reduced following effective
therapeutic treatment that improves symptomatic presentation
(31–33). Importantly, however, although numerous studies
imply a connection between the beta signal and movement
impairments in PD, the causal association is at present
inconclusive (43, 44). However, the changes observed in these
cases are typically modest, offering an inconclusive explanation
for augmented spontaneous beta power as a mechanism for
inhibition of movement. A common limitation of laboratory
studies exploring motor function is the discrete nature of the
tasks, in which participants are typically required to perform
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FIGURE 3 | Beta power accumulation during the serial movement phase. Morlet–wavelet time–frequency spectrograms showing grand average power change,
normalized to the pre-movement period for: (A) placebo and (B) zolpidem. Dashed lines indicate the start and end of movement in each condition. (C) Cumulative
power (nAm2/Hz) in the beta (15–30Hz) frequency bin during performance of the rapid tapping task. Graph demonstrates accumulation of beta power during baseline
and placebo (dashed and solid back) and baseline and zolpidem (dashed and solid red), respectively. A clear increase in beta power is observed in both baseline and
placebo conditions, but not following zolpidem, where suppression below baseline levels occurs. Gray box indicates the time interval where a significant difference (p
< 0.05) can be seen between zolpidem and placebo conditions. (D) Mean cumulative beta (nAm2/Hz) in the baseline-and-placebo (black) and baseline-and-zolpidem
(red) conditions. Significant difference (###p = 0.05) between drug conditions, with a significant difference (*) between zolpidem and baseline (p = 0.03), but not
between placebo and baseline conditions (p = 0.52). (E) Power spectral density plot during the tapping period following placebo (black) and zolpidem (red).
Significant reduction in the beta power to be centered around 25Hz. Gray box shows the 15–30Hz bin used to compute the power change.
individual movements separated by several seconds. Given
that the majority of movements and the impairments that
arise PD are serial in nature and form part of a sequence
of repeated or interconnected actions, it is unsurprising that
studies of discrete individual movements are unable to offer
adequate explanation for the effect of augmented beta power
on movement. Specifically, while mean spontaneous beta power
may be augmented, it is by no means continuous and tends
to manifest as “bursts” of elevated beta power at rest (29, 45),
which is possibly a consequence of the temporal fluctuations in
endogenous dopamine (DA) release (43). A causal association
between elevated beta and impaired movement could be implied
by an increased statistical probability of impaired movement
associated with the burst period, a concept that is supported
by the observed success of adaptive deep brain stimulation,
whereby stimulation is applied in response to elevated beta power
(46). Recent studies in the STN demonstrate that beta bursts
persist during movement and coincide with reduced velocity,
consistent with bradykinesia and with mechanistic theories of
adaptive deep brain stimulation (47, 48). This is in contrast to a
positive correlation between gamma burst amplitude and velocity
(49). Moreover, stimulation of M1 in control participants using
tACS shows that stimulation at beta frequency reduces motion
amplitude during a repetitive movement paradigm (50).
Here, we demonstrate the inhibitory nature of a functionally
related neuronal network feature, perimovement beta. This
observation is consistent with the exaggerated PMBR that we
have previously shown to be abnormally elevated and sustained
in PD (29). PMBR, an inhibitory signature, is unavoidably
generated followingmovement and, therefore, when elevated and
sustained in PD, has a greatly increased probability of impairing
subsequent movements. In the present study, we demonstrate
the impact of an accumulation of beta power (Figure 3C)
and propose this as a critical mechanism in the inhibition
of continuous movement in PD. We further demonstrate the
relationship between the amplitude of individual beta-peak
events and ability of patients to initiate subsequent movements.
The observation of cumulative cortical beta power during
sequential FT is an important addition to our understanding, as
healthy controls exhibit persistent beta suppression in the motor
Frontiers in Neurology | www.frontiersin.org 7 December 2019 | Volume 10 | Article 1298
Prokic et al. GABA Mediated Bradykinesia in Parkinson’s Disease
FIGURE 4 | Perimovement beta power and movement execution. (A) Method for determining the relationship between high perimovement beta and movement
execution. Trace shows rectified electromyography (EMG) trace (example from a single participant) from which the onset of movement was determined (blue
diamonds) and temporally coregistered with the peak of each beta peak (red dots), determined from magnetoencephalography (MEG) virtual electrode (black line
indicates task “Start” cue). (B) The amplitude peak beta (normalized as a percentage of the largest response) was computed following each event and assigned to the
corresponding number of movements (taps) generated in the subsequent ITI. Mean amplitude of beta peaks and lines of best fit are shown for events in the placebo
(black dots and line) and zolpidem (red dots and line) conditions. Plot shows the association between peak beta power and number of taps and significant reduction
in the amplitude of beta in zero movement condition following zolpidem. (C) The mean number of taps per peak beta event (independent of power) is shown for the
placebo (black) and zolpidem (red) conditions. There is no significant difference in the mean number of events but a notable reduction in the variance of the number of
taps following zolpidem. (D) The change in the composition of missed, single, and multiple taps in the placebo (black) and zolpidem (red) condition. A significant
increase (**) in the number of single taps (p = 0.008).
cortex during continuous movement (23), and this is also seen in
the STN of PD patients (21).
GABAergic Improvement of Serial
Movement
There is substantial evidence in support of the role of DA
dysfunction underlying motor symptoms in PD (51). In
particular, a decline in dopaminergic nigrostriatal projections
in the basal ganglia (BG) resulting in reduction in excitatory
drive to the direct pathway and inhibitory drive to the indirect
pathway (52, 53). However, while DA undoubtedly plays a critical
role in regulating the activity of cortico-BG-thalamic circuit,
the predominant connections within this system are GABAergic
and glutamatergic. Within the BG, GABAergic projections are
the predominant connection between the striatum and globus
pallidus [pars interna (GPi) and pars externa (GPe)], GPe to
GPi, GPi to STN, GPi to thalamus, and GPi to brainstem [see
(54) for a summary]. In addition, activity in the M1 and primary
somatosensory cortex (S1) is GABAergically mediated (1, 8, 55,
56). It is, therefore, unsurprising that administration of a specific
GABA-A alpha-1 modulator such as zolpidem elicits a change in
motor function in PD.
These findings raise several important questions on the
mechanistic nature of elevated PMBR and GABA-mediated
desynchronization and improvement in PD. Previous studies
have demonstrated that M1 beta power is driven by GABAergic
interneuron-mediated synchrony, which is contingent upon
excitatory inputs (56). Prevailing PD theories suggest that an
increase in inhibitory GP to thalamic drive reduces excitatory
input to the cortex (57), which suggests that PMBR does
not occur in response to thalamo-cortical inputs. One might
speculate that thalamo-cortical inputs to a putative M1 layer
4 (58) may be temporally aligned to postmovement sensory
feedback from S1. This would present a mechanism for motor
efficiency, whereby sensory information elicits direct influence
over motor feedback from the cortico-BG-thalamocortical loop,
providing an opportunity for optimization through plastic
change. A potential consequence of such integration is the
attenuation of the strength of feedback from S1 to M1,
primarily in layers II/III (59, 60). Given the influence of S1–M1
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connectivity on oscillatory power in the beta frequency range
(55), this presents an appealing hypothesis for PMBR function
and abnormal attenuation in PD. This suggestion is consistent
with that of afferent feedback and sensorimotor recalibration
following a period of change (18).
The mechanism by which GABAergic modulation attenuates
abnormally elevated PMBR, as previously reported (29), is
uncertain. Previous studies observe that GABA-A modulators
augment spontaneous beta power in the motor cortex, through
increased drive to local interneurons in healthy control
participants (1, 2, 55, 56). Further observations in healthy
controls, that PMBR is unaffected by GABA-A modulation (8),
raises the possibility that a separate subcortical mechanism,
involving GABAergic projections in the BG, is a plausible
site of action for the effects observed here. An alternative
cortical mechanism, specific to the low-dose administration of
zolpidem, has previously been described (61), in which low-
dose zolpidem selectively augments interneuron (fast spiking)
specific GABA-A mediated tonic currents, resulting in reduction
in beta oscillatory power. Regardless of the precise mechanism
by which these changes occur, these findings reiterate the
relatively untapped potential for engagement with GABAergic
projections throughout the motor system, as a target for
therapeutic development in PD. The observed zolpidem-specific
improvements and associated oscillatory changes in the present
study raises further questions about the potential impact of
low-dose modulation in non PD participants. While the results
of previous research (29) shows that discrete movements
and associated oscillatory changes are unchanged in healthy
participants, the addition of an age-matched control group would
serve to clarify the current findings further. In conclusion,
these findings provide consistent evidence for the role of beta
oscillations in the symptomatic presentation in PD. In particular,
we demonstrate a mechanistic process whereby cumulative
beta, generated during repeated movement, is disruptive to the
generation of serial motor output. Moreover, we demonstrate
the involvement of GABAergic units in the generation of beta
hypersynchrony, which can be attenuated throughmodulation of
GABA-A alpha-1 receptor activity.
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